Literature DB >> 6434699

Does viloxazine have epileptogenic properties?

J G Edwards, M Glen-Bott.   

Abstract

Six cases of convulsive seizures occurring during treatment with viloxazine notified to the Committee on Safety of Medicines (CSM) and two other cases from Japan were reviewed. A critical study of the patient's histories suggests a possible causal connection between drug and seizures in only two of these cases. The occurrence of convulsions is not in keeping with the results of animal experiments and of clinical trials in which epileptic patients were included, both of which suggest that viloxazine does not have epileptogenic properties and may have anticonvulsant actions. A worldwide review of clinical trials in which unwanted effects have been recorded suggests that viloxazine, even if possessing convulsive properties like other anti-depressants, is probably less epileptogenic than conventional tricyclics and is not contraindicated in epileptic patients requiring antidepressant medication.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434699      PMCID: PMC1027998          DOI: 10.1136/jnnp.47.9.960

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Electrophysiological studies with a new anti-depressant drug: comparison of the effects of viloxazine (ICI 58,834) with three tricyclic anti-depressants in the encéphale isolé.

Authors:  H Neal; P B Bradley
Journal:  Neuropharmacology       Date:  1978-10       Impact factor: 5.250

2.  Convulsive seizures and viloxazine.

Authors:  J G Edwards
Journal:  Br Med J       Date:  1977-07-09

3.  Antidepressants and convulsions.

Authors:  J G Edwards
Journal:  Lancet       Date:  1979 Dec 22-29       Impact factor: 79.321

4.  [Clinical trials of viloxazine in depressive states].

Authors:  M Fontan; M Goudemand; E Pellerin-Millecamps
Journal:  Encephale       Date:  1979       Impact factor: 1.291

5.  Viloxazine: assessment of potential rapid antidepressant action.

Authors:  J G Edwards
Journal:  Br Med J       Date:  1977-11-19

6.  Valium: a discussion of current issues.

Authors:  L E Hollister
Journal:  Psychosomatics       Date:  1977       Impact factor: 2.386

7.  Controlled trial of sulpiride in chronic schizophrenic patients.

Authors:  J G Edwards; J R Alexander; M S Alexander; A Gordon; T Zutchi
Journal:  Br J Psychiatry       Date:  1980-12       Impact factor: 9.319

8.  Electrocortical changes in the encéphale isolé cat following chronic treatment with antidepressant drugs.

Authors:  H Neal; P B Bradley
Journal:  Neuropharmacology       Date:  1979-07       Impact factor: 5.250

9.  Bioavailability and kinetics of maprotiline.

Authors:  D Alkalay; W E Wagner; S Carlsen; L Khemani; J Volk; M F Bartlett; A LeSher
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

10.  Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon.

Authors:  B S Meldrum; G M Anlezark; H K Adam; D T Greenwood
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  7 in total

1.  Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction.

Authors:  F Pisani; A Fazio; C Artesi; M Russo; R Trio; G Oteri; E Perucca; R Di Perri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

2.  Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

Authors:  F Pisani; A Fazio; E Spina; C Artesi; B Pisani; M Russo; R Trio; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

4.  Viloxazine and anticonvulsants.

Authors:  M R Trimble
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

5.  Carbamazepine-viloxazine interaction in patients with epilepsy.

Authors:  F Pisani; A Fazio; G Oteri; E Perucca; M Russo; R Trio; B Pisani; R Di Perri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

Review 6.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 7.  Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Authors:  Robert L Findling; Shawn A Candler; Azmi F Nasser; Stefan Schwabe; Chungping Yu; Jennie Garcia-Olivares; Welton O'Neal; Jeffrey H Newcorn
Journal:  CNS Drugs       Date:  2021-05-18       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.